Similar articles for PMID: 26214065

Year	Number of Results
1966	1
1991	1
1992	1
2000	1
2001	1
2002	1
2003	1
2004	4
2005	1
2006	3
2007	1
2008	2
2009	3
2010	3
2011	2
2012	2
2014	3
2015	5
2016	4
2017	3
2018	1
2020	2
2021	1
2022	1
2023	1
2024	0

1

No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of nebivolol in healthy Chinese subjects.

Luo X, Lei Y, He L, Liu W, Li M, Ran L, Yu M, Guo X, Yu P, Liu Z, Cheng Z. Luo X, et al. J Clin Pharm Ther. 2015 Oct;40(5):561-565. doi: 10.1111/jcpt.12310. Epub 2015 Jul 27. J Clin Pharm Ther. 2015. PMID: 26214065

2

Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.

Guo L, Wang S, Wan Z, Ni S, Xu B, Zhao X, Liu L. Guo L, et al. J Clin Pharm Ther. 2020 Aug;45(4):632-637. doi: 10.1111/jcpt.13155. Epub 2020 May 7. J Clin Pharm Ther. 2020. PMID: 32379356

3

Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.

Pei Q, Peng J, Tan H, Yang L, Yang X, Liu L, Liu S, Yuan H, Yang G. Pei Q, et al. Eur J Drug Metab Pharmacokinet. 2015 Dec;40(4):427-33. doi: 10.1007/s13318-014-0221-x. Epub 2014 Aug 27. Eur J Drug Metab Pharmacokinet. 2015. PMID: 25159483 Clinical Trial.

4

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.

Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y. Lefebvre J, et al. Br J Clin Pharmacol. 2007 May;63(5):575-82. doi: 10.1111/j.1365-2125.2006.02796.x. Epub 2006 Nov 10. Br J Clin Pharmacol. 2007. PMID: 17094780 Free PMC article. Clinical Trial.

5

Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.

Qiu F, Liu S, Miao P, Zeng J, Zhu L, Zhao T, Ye Y, Jiang J. Qiu F, et al. Eur J Clin Pharmacol. 2016 Jun;72(6):689-95. doi: 10.1007/s00228-016-2048-7. Epub 2016 Mar 29. Eur J Clin Pharmacol. 2016. PMID: 27023460 Clinical Trial.

6

Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.

Vieira CP, Neves DV, Coelho EB, Lanchote VL. Vieira CP, et al. Drug Metab Lett. 2018;12(1):68-70. doi: 10.2174/1872312812666180420104945. Drug Metab Lett. 2018. PMID: 29676238

7

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.

Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA. Zineh I, et al. Clin Pharmacol Ther. 2004 Dec;76(6):536-44. doi: 10.1016/j.clpt.2004.08.020. Clin Pharmacol Ther. 2004. PMID: 15592325

8

Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.

Lim KS, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Cho JY, Shin SG, Yu KS. Lim KS, et al. Clin Ther. 2010 Apr;32(4):659-66. doi: 10.1016/j.clinthera.2010.04.002. Clin Ther. 2010. PMID: 20435235

9

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.

Swaisland HC, Cantarini MV, Fuhr R, Holt A. Swaisland HC, et al. Clin Pharmacokinet. 2006;45(6):633-44. doi: 10.2165/00003088-200645060-00006. Clin Pharmacokinet. 2006. PMID: 16719544 Clinical Trial.

10

Evaluation of 24 CYP2D6 Variants on the Metabolism of Nebivolol In Vitro.

Hu X, Lan T, Dai D, Xu RA, Yuan L, Zhou Q, Li Y, Cai J, Hu G. Hu X, et al. Drug Metab Dispos. 2016 Nov;44(11):1828-1831. doi: 10.1124/dmd.116.071811. Epub 2016 Aug 18. Drug Metab Dispos. 2016. PMID: 27538917

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

44 results

Results by year